AAO 2023: Company updates from Centricity Vision CEO Rob Thornhill

News
Article

At this year's American Academy of Ophthalmology meeting in San Francisco, California, Rob Thornhill, CEO of Centricity Vision, spoke with the Ophthalmology Times team about developments in the company's ZEPTOLink IOL positioning systems.

Rob Thornhill, CEO of Centricity Vision, spoke with the Ophthalmology Times team about the company's newest developments at this year's American Academy of Ophthalmology meeting.

Video Transcript

Editor's note - This transcript has been edited for clarity.

Rob Thornhill:

Good morning, my name is Rob Thornhill. I'm the CEO of Centricity Vision, the developer and manufacturer of ZEPTO and ZEPTOLink IOL positioning systems. Were excited to announce the commercial launch of our newest innovation, ZEPTOLink, here at the [American] Academy of Ophthalmology in San Francisco.

ZEPTOLink, as well as our legacy ZEPTO systems, are the first and only devices that create an instantaneous capsulotomy with precise 360 degree overlap and superior capsular edge strength, making our technology ideal for advanced technology intraocular lenses and complex cases, requiring enhanced precision. ZEPTOLink combines the clinically proven ZEPTO technology with any phacoemulsification device. This combination saves time and space in the operating room. A combination of 12 new and existing accounts, as well as 22 surgeons, participated in our soft launch over the last 3 months and successfully completed over 500 ZEPTOLink cases. The surgeons liked the intuitive use of the phaco foot pedal that allowed them to precisely control suction, energy delivery and irrigation. Universally, they recognise the enhanced speed of the ZEPTO system which leads to enhanced workflow efficiency, especially when compared to a laser system.

With the increasing cost of all goods and services, including cataract surgery, ZEPTO technology, at 1/10 the capital cost in one-half the per use cost of a laser, provide surgeons and their patients with a cost effective alternative when considering advanced technology IOL surgery. Thank you.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.